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Introduction: Mesenchymal stem cells (MSCs) have immunosuppressive activity. They do not induce allospecific T
cell responses, making them promising tools for reducing the severity of graft versus host disease (GVHD) as well as
treating various immune diseases. Currently, there is a need in the MSC field to develop a robust in vitro bioassay
which can characterize the immunosuppressive function of MSCs.
Methods: Murine clonal CD4 and CD8 T cells were stimulated with cognate peptide antigen and antigen
presenting cells (APCs) in the absence or presence of human MSCs, different aspects of T cell activation were
monitored and analyzed using flow cytometery, real time RT-PCR and cytokine measurement.
Results: Human MSCs (hMSCs) can alter multiple aspects of murine T cell activation induced by stimulation with
specific antigen, including: reduced proliferation, inhibited or stimulated cell surface marker expression (CD25, CD69,
CD44 and CD62L), inhibited mRNA expression of transcription factors (T-bet and GATA-3) and decreased cytokine
expression (interferon-gamma, interleukin-10). Disappearance of activation-induced cluster formation and decreased
apoptosis of CD8 T cells were also observed. Moreover, the effects are specific to MSCs; incubating the T cells with
non-MSC control cell lines had no effect on T cell proliferation and activation.
Conclusions: Clonal murine T cells can be used to measure, characterize, and quantify the in vitro immunosuppressive
activity of human MSCs, representing a promising approach to improve bioassays for immunosuppression.Introduction
Mesenchymal stem cells (MSCs) are mesoderm-derived
cells that are found in virtually all tissues and function
as precursors of non-hematopoietic connective tissues
with the capacity to differentiate into mesenchymal and
non-mesenchymal cell lineages. They are the precursors of
three main cell types of the mesodermal lineage, including
osteocytes, chondrocytes and adipocytes [1-3]. These cells
are commonly described as positive for CD73, CD105 and
CD90 and negative for hematopoietic (CD45) and vascular
(CD31) markers [4]. Their properties have been extensively
studied in recent years. Since MSCs are capable of* Correspondence: chenghong.wei@fda.hhs.gov
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reproduction in any medium, provided the ordifferentiating into several cell lineages [5], they have been
used in investigational studies to treat a variety of tissue
injuries both in experimental and clinical settings [6-8].
An interesting aspect of MSCs is the finding that they
exert immunoregulatory activities. MSCs from various
species (human, rodents and primates) can suppress the T
cell response to mitogenic and polyclonal stimuli [9,10]
and to specific peptide antigens [11]. MSCs have a similar
effect on both memory and naïve T cells [12], as well as
both CD4+ and CD8+ subsets [13]. The immunosuppres-
sive effects of MSCs make them attractive candidates for a
variety of cellular therapies, including treatment of immune
disorders.
MSCs express low levels of MHC I and do not express
MHC II or co-stimulatory molecules; they are, therefore,
considered to be immune privileged cells and can be
successfully transplanted across allogeneic barriers [14].
In addition, large amounts of MSCs can potentially bel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have promoted wide application of MSCs in clinical trials
to treat various immune diseases, including multiple
sclerosis, Crohn’s disease, type 1 diabetes, systemic lupus
erythematosus (SLE) and acute and chronic graft versus
host disease (GVHD) [15,16]. Mouse models have been
used to test the efficacy for the treatment of GVHD,
neurological and systemic autoimmune diseases, sepsis, and
acute renal and lung injury, as well as other pathological
conditions [17].
Due to the low frequency of MSCs in the bone marrow
and the potential for allogeneic therapy, MSCs need to be
extensively expanded and passaged to obtain sufficient cell
numbers for cell therapies. Therefore, there is a need to
understand the role of cell expansion, cell passaging, and
donor differences on MSC immunosuppressive capacity.
Currently, there are no robust quantitative bioassays
suitable for measuring differences in immune-inhibitory
activity of MSCs from different donors or at different
passages, or under different conditions in large-scale tissue
culture expansion. There is a related scientific need to iden-
tify the molecular mechanisms underlying MSC-mediated
immunosuppression, which also requires accurate assays
to measure the immunosuppressive activity of MSCs. Such
methods could potentially be used to assess MSCs prepara-
tions from various donors and expansion methods or to
predict MSC behavior after transplantation.
To address these issues, we developed novel immune
inhibition assays using clonal murine T cell populations
responding to known peptide antigens, and MSCs derived
from human donors. MSCs are known to be immunosup-
pressive across xenogeneic barriers [18,19], allowing us to
assess the use of easily obtained clonal murine T-cells as a
method to reduce variability in T-cell based in vitro
immune suppression assays. Using this system we assessed
the immunosuppressive activity of human bone marrow-
derived MSCs (hMSCs) on antigen specific, clonal murine
T cells. In our system, hMSCs clearly show dose-dependent
inhibitory properties, affecting both the proliferation and
the activation of antigen specific T cells. We also were able
to use this system to investigate some of the molecular
mechanisms that participate in cross-species immunosup-
pression, which may potentially shed light on allogeneic
immunosuppressive activities of hMSCs.
Methods
Ethics statement
All animal protocols and procedures were approved by
the Institutional Animal Care and Use Committees at
the Center for Biologics Evaluation and Research (CBER;
Protocol #2011-15) and in animal facilities accredited by
the Association for Assessment and Accreditation of
Laboratory Animal Care International. All experiments
were performed according to institutional guidelines.Cell culture
hMSCs were purchased (AllCells, Emeryville, CA, USA)
at passage one. According to the manufacturer’s and our
characterizations, MSCs were negative for hemaotopoietic
lineage markers, including CD45, CD34, CD14, CD79α,
CD117 and HLA-DR. MSCs were plated in T175 flasks
(Greiner Bio-One, Monroe, NC, USA) at 60 cells/cm2,
expanded in α-MEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 16.5% fetal bovine serum (FBS)
(JMBioscience, San Diego, CA, USA), Pen Strep and L-
glutamine (Invitrogen), and cultured at 37°C and 5% CO2.
At 80% confluence, 0.25% Trypsin/EDTA (Invitrogen) was
used to harvest MSCs. Cells were washed, then cryopre-
served in freezing medium containing 5% Dimethyl sulfox-
ide (DMSO) (Sigma-Aldrich, St. Louis, MO, SA), 30% FBS,
1% penicillin (100 units/ml) and streptomycin (100 μg/ml)
(Invitrogen) at 1 × 106 cells/ml at passage three (P3).
hMSCs at P3 were thawed, cultured to 80% confluence
and harvested for experiments.
The HT-1080 fibrosarcoma cell line was purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA). The cell line was plated in T175 flasks, expanded in
RPMI-1640 medium supplemented with 10% FBS, Pen
Strep and L-glutamine, and cultured at 37°C and 5% CO2.
Cells at P3 were harvested with Trypsin/EDTA and used
in experiments.
Flow cytometry analysis
hMSCs were incubated with 2.4G2 antibody at 4°C for
30 minutes to block non-specific binding. Primary anti-
bodies used were purchased conjugated to their respect-
ive fluorochromes (phycoerythrin (PE); allophycocyanin
(APC); fluorescein isothiocyanate (FITC)): anti-CD29-
APC, anti-CD44-APC, anti-CD90-FITC, anti-CD73-PE
(BD Biosciences, San Jose, CA, USA), anti-CD166-FITC
(US Biological, Salem, MA, USA), anti-CD105-PE (Beck-
man Coulter, Brea, CA, USA) and anti-STRO-1-
Alexa647 (Biolegend, San Diego, CA, USA). MSCs were
also analyzed for negative markers, including anti-CD34-
PE, anti-CD45-PE-Cy7, anti-CD14-ECD, anti-CD79α-PE-
Cy5, anti-CD117-APC (Beckman Coulter) and anti-HLA-
DR-FITC (BD Biosciences). hMSCs were incubated with
antibody at optimized concentrations for 30 minutes at 4°C.
Samples were centrifuged, washed twice with phosphate-
buffered saline (PBS)/1% fetal bovine serum/0.2% sodium
azide, and analyzed in single color using FACSCalibur
(Becton Dickinson) or FACS Canto flow cytometers. For
flow cytometry analysis of T cells, anti-CD4, anti-CD8,
anti-T cell receptor (TCR) Vβ4, anti-TCR Vβ8.1/8.2,
anti-CD25, anti-CD69, anti-CD62L, anti-CD44 in vari-
ous fluorochrome combinations were purchased from BD
Biosciences. For all surface marker analysis, TCR trans-
genic CD4+ T cells (BDC2.5 T cells) were first gated using
CD4 and TCR Vβ4 double staining, while CD8+ TCR
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and TCR Vβ8.1/8.2 double staining. Annexin V/7 AAD
apoptosis detection kit was purchased from BD Biosci-
ences. CFSE (carboxyfluorescein diacetate, succinimidyl
ester) was purchased from Invitrogen (Carlsbad, CA) and
was used according to the manufacturer’s instructions.
Mice
NOD/ShiLtj mice, Nonobese diabetic 8.3 TCR transgenic
mice (NOD 8.3) and Nonobese diabetic BDC2.5 TCR
transgenic mice (NOD BDC2.5) were purchased from
Jackson Laboratories (Bar Harbor, ME, USA) and were
maintained in specific pathogen-free conditions according
to the guidelines of CBER’s Institutional Animal Care and
Use Committee (IACUC). The BDC2.5 TCR transgenic
CD4+ T cells specifically recognize the I-Ag7 restricted
epitope derived from an islet antigen [20], and the 8.3
TCR transgenic CD8+ T cells specifically recognize the
Kd-restricted IGRP206-214 epitope derived from the islet
antigen IGRP (islet-specific glucose-6-phosphatase catalytic
subunit-related protein) [21]. These studies were approved
by the IACUC of CBER.
Immunosuppression assay
Spleens and lymph nodes were isolated from NOD 8.3 and
NOD BDC 2.5 TCR transgenic mice, then CD4 and CD8 T
cells were negatively selected and purified using the mouse
CD4+ T cell isolation kit and CD8+ T cell isolation kit,
respectively (Miltenyi Biotec, Auburn, CA, USA). T cells
were added to 24-well plates (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) (2 × 106 cells/well). Total sple-
nocytes from NOD/ShiLtj mice were irradiated at 4,000
rads and added to the culture as antigen-presenting cells
(APCs) (4 × 106 cells/well). In all the experiments APCs
are irradiated. Islet-specific glucose-6-phosphatase cata-
lytic subunit–related protein (IGRP206-214, VYLKTNVFL)
and BDC 2.5 peptides (RVRPLWVRME) were synthesized
by the FDA FBR (Facility for Biotechnology Resources)
core facility. Peptides were added to a concentration of
1 μg/ml per well. Next, human MSCs were trypsinized,
washed and added to the wells at different T cell: MSC ra-
tios. Ratios of 10:1 and 5:1 were found to be effective for
our conditions and were used in all experiments. Cells
were kept in RPMI 1640 complete medium (containing
10% FBS) in a 37°C incubator for three days after which
murine T cells were harvested and analyzed.
For the immunosuppression assay using a transwell
setup, hMSCs were cultured on the top level of the HTS
Transwell®-24 Well plate with 0.4 μm pores (Corning,
Lowell, MA USA) and the T cells together with the irra-
diated APCs and peptide were cultured in the bottom
wells in the same ratios as described above. The cells
were grown for three days at 37°C after which they were
harvested and analyzed.Cytokine analysis
Supernatants were collected at Day 3 of cell culture and
stored at -80°C for further analysis. Cytokine concentration
was measured using the Mouse Th1/Th2 6-plex Panel
kit from Invitrogen according to the manufacturer’s in-
structions. Samples were acquired and analyzed using a
Bio Plex 200 instrument (BioRad, Hercules, CA, USA).
Real time RT-PCR
Total RNA was extracted from suspension T cells using
Pure Link Micro-to Midi RNA extraction kit (Invitrogen),
quantified using a Nanodrop 1000 spectrophotometer
(Thermo Scientific, Asheville, NC, USA) and stored at -80°C
for further analysis. RNA integrity was assessed using
an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA) and the RIN (RNA Integrity Number)
values were all greater than 9.20. Taqman RT-PCR probes
for murine transcription factors T-bet and GATA-3 were
purchased (from customized probes) from Applied Biosys-
tems (Foster City, CA). A total of 200 ng of RNA was
reverse transcribed into cDNA using a High capacity cDNA
Reverse Transcription kit from Applied Biosystems. cDNA
was specifically amplified using the ABI 7900 instrument
from Applied Biosystems. 18S rRNA was used as endogen-
ous control in all samples. Results were analyzed using SDS
2.3 software (Applied Biosystems).
Statistical analysis
Data were analyzed using GraphPad Prism 5 software
(GraphPad, La Jolla, CA, USA), and Student’s t-test was
used to compare differences between samples and groups.
The differences were considered statistically significant
when P-value was below 0.05.
Results
Human mesenchymal stem cells show typical cellular
and functional phenotype
The hMSC line used in this study, PCBM 1632, demon-
strated tri-lineage differentiation toward adipo-, osteo- and
chondro-genic lineages when using standard induction
protocols (Miltenyi-Biotech) (data not shown). The MSC
line expressed markers typical of hMSCs [22]. Passage 3
hMSCs show high positive expression for MSC surface
markers: CD29 (93.6%), CD44 (98.4%), CD166 (98.3%),
CD90 (93%), CD73 (99.6%) and CD105 (98.6%). A small
subset of hMSCs (16.9%) was positive for STRO-1, a
marker thought to be associated with a clonogenic and
more immunosuppressive subpopulation of MSCs [23].
hMSCs inhibit the proliferation of murine T cells
Murine TCR transgenic CD4+ and CD8+ T cells were
isolated from NOD/BDC 2.5 mice and NOD/8.3 mice,
respectively. They were co-cultured for three days together
with irradiated (4,000 rads) total spleen cells from NOD/
Nazarov et al. Stem Cell Research & Therapy 2013, 4:128 Page 4 of 15
http://stemcellres.com/content/4/5/128ShiLtj mice acting as APCs. The human MSCs were added
to the culture and the proliferation of the T cells was
monitored by CFSE dilution assay (Figure 1). After three
days in culture, the control T cells that were not stimulated
by their cognate peptides in the presence of APCs showed
minimal or no proliferation, whereas the T cells that were
stimulated by specific peptide showed substantial prolifera-
tion as indicated by CFSE staining. The optimal concentra-
tion of the peptide to stimulate the T cells was found to be
1 μg/ml, after multiple experiments in which different
concentrations were used. T cells were co-incubated with
human MSCs at different ratios. The T cells that we
co-incubated with human MSCs at a ratio of 10:1 showed
a decrease in proliferation (67.3% for CD4+ T cells and
76.1% for CD8+ T cells), as compared with T cells that we
stimulated in the absence of MSCs (82.6% for CD4+ T
cells and 87.5% for CD8+ T cells). Additionally, incubating
the T cells with a higher ratio of MSCs (5:1) showed an
even larger decrease in the percentage of divided cells
(59.9% for CD4+ T cells and 58.2% for CD8+ T cells). We
performed additional experiments using several other
ratios (20:1, 50:1, 100:1) and did not see any immuno-
suppression using these lower ratios (data not shown).
These results show an inhibitory effect of hMSCs on
murine T cells in an in vitro setting. The extent of
inhibition is dependent on the ratio of hMSCs to T cells,
with more MSCs per T cell causing more inhibition.Figure 1 hMSCs inhibit antigen-induced murine T-cell proliferation. A
cells (B) were activated by their cognate peptides in the presence of antig
marrow-derived mesenchymal stem cells (hMSCs) in two different ratios (1
72 hours later and analyzed by FACS. TCR transgenic CD4+ T cells (BDC2.5
CD8+ TCR transgenic CD8 T cells (8.3 T cells) were gated using CD8 and TCR V
undivided T cells (right hand bars) and divided T cells (left hand bars) are show
experiments with similar results.After three days in culture, the cells were examined by
microscope. The stimulated CD8+ T cells show a change
in morphology (formation of large clusters) as opposed
to the non-stimulated T cells (Figure 2). Co-incubation
with hMSCs shows a dramatic change in appearance, the
clusters completely disappear, no clusters can be found at
both 10:1 and 5:1 ratio.
hMSCs affect the expression of different murine T cell
activation markers
Murine T cells were activated as described in the Materials
and methods section and co-cultured with hMSCs. After
three days in culture, cells were stained for various activa-
tion markers (Figure 3). In both CD4 and CD8 positive T
cells, the analyzed markers show an increased expression
after incubation with peptide and APC. CD25 expression
was significantly decreased (greater than nine-fold decrease
in mean fluorescence intensity (MFI)) after co-incubation
with hMSCs in both ratios (10:1 and 5:1). CD69 showed a
similar pattern of expression to CD25, being significantly
inhibited (three-fold decrease in MFI) by hMSCs, whereas
CD44 was only slightly decreased by hMSCs in both CD4+
T and CD8+ T cells. The effect on both CD25 and CD69
was hMSC dose-dependent, as greater inhibition of both
markers was seen at a ratio of 5:1 compared to 10:1.
For CD62L we observed a differential effect of hMSCs
on CD4+ T cells vs. CD8+ T cells. In both CD4+ T cellstotal of 2 × 106 purified antigen specific murine CD4+ (A) and CD8+ T
en-presenting cells (APCs), and then co-cultured with human bone
0:1 and 5:1). T cells were CFSE labeled on Day 0 and then harvested
T cells) were first gated using CD4 and TCR Vβ4 double staining, while
β8.1/8.2 double staining. The gates used to determine the percentage of
n in each panel. The graphs are representative of four different individual
Figure 2 hMSCs inhibit formation of clusters following T cell activation. The figure shows bright field images (40X) of CD8+ T cells
un-stimulated or stimulated with specific peptide (upper panels), or incubated with human bone marrow-derived mesenchymal stem cells (hMSCs)
in two ratios (lower panels) for 72 hours. Untreated hMSCs are shown on the lower right. The results are representative of more than 10 different
individual experiments with similar findings. Scale bars represent 100 μm.
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of CD62L was up-regulated upon stimulation with cognate
peptides. Interestingly, in CD4+ T cells the expression of
CD62L is more homogeneous, whereas in CD8+ T cells we
observed two peaks in the expression pattern, correspond-
ing to a low-expressing population and a high-expressing
population. The hMSCs down-regulated the expression
of CD62L in CD4+ T cells (especially at the 5:1 ratio), as
indicated by MFI; but in the CD8+ T cells, hMSCs co-
incubation lead to an increase in the “high-expression”
peak and a slight increase of MFI.
hMSCs can affect the activation of murine T cells
stimulated with anti-CD3/anti-CD28 beads
In the literature, other methods have been used to evaluate
the immunoregulatory property of hMSCs, some of them
use the antigen-unspecific system, such as the anti-CD3/
anti-CD28 induced T cell activation. To assess whether
anti-CD3/anti-CD28 stimulated murine T cell activation
can also be inhibited by hMSCs, we activated purified mur-
ine antigen-specific CD8 TCR transgenic T cells (8.3 T cells)
with Dynabeads (Invitrogen) conjugated with anti-CD3/
anti-CD28 mAbs at 1:1 ratio and analyzed the T cell acti-
vation markers (CD25, CD69) on the murine 8.3 T cells.
As shown in Figure 4, hMSCs can also efficiently inhibit
the anti-CD3/anti-CD28 induced up-regulation of CD25
and CD69 on murine antigen-specific CD8+ T cells.
Also, we have checked the impact of hMSCs on surface
markers of already activated murine CD8+ T cells (8.3 T
cells). As shown in Additional file 1: Figure S1, the hMSCs
do not have an inhibitory effect on surface markers of
activated T cells.CD8+ T cell apoptosis is affected by hMSCs
There are contradictory data in the literature concerning
the effect of hMSCs on the viability of T cells. Some reports
show that the hMSCs induce apoptosis when co-cultured
together with human T cells, while others observe that
hMSCs lead to a cell cycle arrest of the human T cells
[13,24,25], but do not induce apoptosis. We wanted to
determine whether hMSCs induce murine T cell apoptosis
in our system; therefore, three days after co-culturing the
T cells together with their cognate peptide and APC plus
hMSCs, we performed an apoptosis assay. The cells were
counted and then stained with annexin V and 7AAD.
7AAD negative and annexin V positive cells were defined
as apoptotic. The results depicted in Figure 5 show
annexin V expression in both populations analyzed (CD4+
and CD8+ T cells). Again, the results showed a differential
effect of hMSC on murine CD4+ and CD8+ T cells.
Only a fraction of the CD4+ T cell population stained
positive for Annexin V after being stimulated with a
specific peptide and APCs (16%). Co-culture with hMSCs
at both 10:1 and 5:1 ratios slightly increased the number
of annexin V positive cells (21.7% to 25%), supporting
the idea that hMSCs only marginally affect the viability
of CD4+ T cells.
Conversely, stimulated CD8+ T cells showed a significant
number of apoptotic cells (82.7%) after three days in
culture. Incubation with hMSCs led to a decreased
number of apoptotic cells (42.2%, 30%), suggesting that
hMSCs seem to contribute to a better survival of these
CD8+ T cells in culture. The effect seems to be dose
dependent, with the ratio of 5:1 showing a more signifi-
cant effect on the T cells.
Figure 3 hMSCs effect on different activation markers on murine antigen-specific T cells. Murine CD4 (A) and CD8 (B) T cells were isolated
and purified from lymph nodes and spleens of TCR transgenic mice using Miltenyi mouse CD4+ T cell/CD8+ T cell isolation kit and cultured for
three days in the presence of specific peptides and APCs. Human bone marrow-derived mesenchymal stem cells (hMSCs) were added to the
wells at the beginning of the culture in two ratios (1:10 and 1:5 hMSC to T cells). The cells were harvested and stained with antibodies specific for
activation markers as indicated below each panel. Each graph shows overlays of histograms representing each condition as shown in the key:
unstimulated T cells - red; stimulated T cells - blue; stimulated T cells + hMSC (ratio 10:1) - green; stimulated T cells + hMSC (ratio 5:1) - orange.
The bar graphs depict the mean fluorescence intensity (MFI) of the analyzed surface markers on T cells in different treatment groups. All graphs
are representative of three individual experiments with similar results.
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important transcription factors
In order to further examine the effects of hMSCs on
murine T cells at the molecular level, we then analyzed
mRNA expression patterns. Total RNA was extracted
48 hrs after co-culturing the T cells with hMSC, and
then subjected to reverse transcription and real time
RT-PCR with specific probes for murine T-bet and
GATA-3 transcription factors. There is a significant
increase in expression of both transcription factors
after activation of CD4+ T cells, while after activation
of CD8+ T cells we only observed notably increased
expression of T-bet (Figure 6). T-bet gene expression
level was increased 125 times in CD4+ T cells and
approximately 60 times in CD8+ T cells compared with
the un-stimulated cells. GATA-3 gene expression level
was increased 8 times in CD4+ T cells and 1.7 times inCD8+ T cells compared with the un-stimulated T cells.
Stimulation in the presence of hMSCs led to decreased
transcription factor expression in both CD4+ and CD8+ T
cell population, with GATA-3 showing a more signifi-
cant reduction in gene expression than T-bet in CD4+
T cells. It has been previously reported that hMSCs
have a preferential inhibitory activity on Th1 cells [26],
but in our system GATA-3 (a hallmark transcription
factor for the Th2 subset) was more significantly af-
fected by hMSCs, while T-bet was affected to a lesser
extent. The inhibitory effect of hMSCs on both tran-
scription factors is in agreement with the effect on
activation marker expression at the surface and to our
knowledge is the first report of the effect of hMSCs on
murine T cells at the molecular level. The results were
consistent, as we repeated the experiments three times
and found similar results.
Figure 4 hMSCs also inhibit the activation of T cells stimulated with anti-CD3/anti-CD28 beads. Mouse Ag specific CD8+ T cells (8.3 T cells)
were activated using anti-CD3/anti-CD28 Dynabeads (Invitrogen) (1:1 ratio) and IL-2 (2,000 U/ml) for three days in the presence or absence of human
bone marrow-derived mesenchymal stem cells (hMSCs) at the ratio of 5:1 T cells:MSC. Expression of activation markers (CD25, CD69) was evaluated by
flow cytometry and the mean fluorescence intensity (MFI) was shown for each marker. The values are representatives of three separate experiments.
Nazarov et al. Stem Cell Research & Therapy 2013, 4:128 Page 7 of 15
http://stemcellres.com/content/4/5/128hMSCs affect the secretion of cytokines by CD4+
and CD8+ T cells
It has been shown that hMSCs inhibit the production of
various cytokines by T cells both in vitro and in vivo
[27]. We wanted to assess if cytokine production is also
inhibited in our system. Supernatants were collectedFigure 5 hMSCs protect CD8+ T cells from apoptosis. Negatively select
presence of specific peptide and APCs for three days. Cells were stained w
instrument. Results were analyzed using (Tree Star, Inc., Ashland, OR) softw
panels. The histograms are representative of three independent experimen
mine the percentage of apoptotic cells after treatment. hMSCs, human bonfrom samples 72 hours after the initial setup. We analyzed
six murine cytokines using the Th1/Th2 multiplex ELISA.
The levels of all six murine cytokines analyzed: IL-10,
IFN-γ, IL-12, IL-5, IL-4 and IL-2 showed similar patterns
of expression (the values of IL-12 and IL-5 were very low;
therefore, the data were now shown). As expected, theed CD4 and CD8 murine T cells were co-cultured with hMSC in the
ith annexin V - APC and analyzed immediately on a FACS Canto II BD
are. The experimental conditions are shown to the left of each set of
ts with similar results. The horizontal bar shows the gate used to deter-
e marrow-derived mesenchymal stem cells.
Figure 6 hMSCs inhibit expression of T-bet and GATA-3 in murine CD4+ and CD8+ T cells. Total RNA was extracted from murine T cells
48 hrs after stimulation with specific peptides and co-culturing with human bone marrow-derived mesenchymal stem cells (hMSCs). The RNA
was reverse transcribed into cDNA and specifically amplified using probes for murine T-bet and GATA-3. Bars in each panel represent fold change
of mRNA expression as compared with un-stimulated T cells. Results for CD4+ T cells are shown in panel A and for CD8+ T cells in panel B. Every
assay was done in triplicate, values are expressed as the mean and SD of triplicates. Statistical analysis was carried out by applying the Student’s
t- test. *indicates P <0.05 for differences between conditions shown by the horizontal brackets. The results shown represent one out of three
independent experiments with similar results.
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cells as compared with the non-stimulated cells. After
co-culturing with hMSCs the amount of murine cytokines
secreted in the medium was significantly lower than seen
for activated T cells. This holds true for both the CD4+
and CD8+ populations. IFN-γ was the most abundantly
secreted cytokine after stimulation of both CD4+ and
CD8+ T cells (Figure 7). The concentration of IFN-γ
secreted by the activated CD8+ T cells (19,000 pg/ml)
was significantly higher than that secreted by the CD4+ T
cells (3,500 pg/ml). The hMSCs lowered the concentration
of secreted IFN-γ by both CD4+ and CD8+ T cells in a dose
dependent manner. This is in agreement with previous
reports showing a reduction in the cytokine secretion
ability of T cells after they are incubated with hMSCs
[11]. Differing from previous reports showing that
hMSCs promote production of Th2 cytokines [24,26],
we found that in this system the clonal murine CD4+
and CD8+ T cells that were incubated with hMSCs
secreted a lower amount of IL-10 (a Th2 cytokine) when
compared with the activated T cells. The effect was more
evident on CD4+ T cells, as they are better IL-10 secretors
than CD8+ T cells. All these results clearly demonstrate
the inhibitory effect that hMSCs have on murine T cells inan in vitro system. Since hMSCs inhibited IFN-γ secretion
by both CD4 and CD8 T cells in a dose dependent manner,
this assay could be used to quantitatively measure the
immunosuppressive activity of hMSCs.
Since Treg and Th17 cells are also important regulators
in the immune system, the effects of hMSCs on these T
cell subsets were checked as well. As shown in the
Additional file 2: Figure S2, we did not see remarkable
changes in the frequencies of Treg and Th17 cells in
the presence of hMSCs.
Human fibrosarcoma cells do not have any effect on the
proliferation and activation of murine T cells
To demonstrate that the inhibitory effect that hMSCs
have on murine T cells is specific to the hMSCs, we
also used a different adherent human cell line in our
experiments, HT-1080 (human fibrosarcoma cell line).
These cells have similar morphological features to hMSCs,
without having any known MSC-like properties (the
multi-potent ability to differentiate into osteocytes, chon-
drocytes and adipocytes); therefore, they are used as
controls in our experiments. We used these cell lines in
the same ratios as the hMSCs, and the same experimental
settings.
Figure 7 hMSCs inhibit secretion of Th1/Th2 cytokines by antigen stimulated murine T cells. Murine CD4+ (panel A) or CD8+ (panel B) T
cells were cultured in the same conditions as described earlier (2 × 106 cells/well), together with their specific peptide and APCs. Human bone
marrow-derived mesenchymal stem cells (hMCSs) were added to the T cells in the ratios 1:10 and 1:5 and supernatants were collected 72 hours
later. Cytokine secretion was quantified and results are shown as pg/ml on the y axis. Shown are representative data out of two independent
experiments with similar results. The samples were set up in triplicates in each experiment. Cytokine concentrations are represented in pg/ml for
each sample, and results are expressed as the mean and SD of triplicates. *indicates P <0.05 for differences between conditions shown by the
horizontal brackets.
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different experiments conducted with each cell line. First,
proliferation as shown by CFSE staining is not affected by
the control cell line, with the percentage of undivided cells
remaining the same even after incubation with human
fibrosarcoma cells in a ratio of 5:1. Second, unlike hMSCs,
both CD25 and CD69 expression on CD4+ T cells were
not inhibited by the control cell line. On the contrary,
there seems to be a slight increase in the expression of
these two activation markers in CD4+ T cells when
HT-1080 is present at one per 5 T cells, but not one
HT-1080 per 10 T cells. The same effect was observed
in CD8+ T cells (data not shown). It has been suggested in
the literature that human fibroblasts have an inhibitory
effect on the immune system, similar to hMSCs [28], albeit
by a different mechanism than mesenchymal stem cells.
We tested that hypothesis by using primary human dermal
fibroblasts in our experiments. The fibroblasts do not haveany inhibitory effect on the T cells, supporting our claim
that the immuno-suppressive effect in our system is
specific to the hMSCs (data not shown).
The immuno-suppressive effect of hMSCs is cell
contact-dependent
There has been widespread interest in elucidating the
mechanism by which hMSC act as suppressors of the im-
mune system. It is accepted that hMSCs act by cell-cell
contact inhibition and by secreting soluble factors in vitro
as well as in vivo [29].
We aimed at understanding the mechanism by which
hMSCs affect the proliferation and activation of murine
antigen specific T cells in our in vitro system. The CD4+
T cells or CD8+ T cells were cultured together with their
cognate peptides and APCs in the bottom wells of a 24-well
transwell system plate. In the upper wells we cultured the
hMSCs in the same ratios as previously.
Figure 8 Human fibrosarcoma cells do not affect mouse T cells proliferation and activation. Murine CD4+ T cells were labeled with CFSE
and incubated with their cognate peptide and APCs for three days with or without human fibrosarcoma cells HT-1080. A total of 72 hours later,
the cells were analyzed for the CFSE profile (A) and for the expression of two activation markers: CD25 (B) and CD69 (C). The unstimulated CD4+ T cells
are represented by a red histogram, the stimulated T cells by a blue histogram and the cells that were co-cultured with human epithelial
cells are represented as green (ratio 10:1) and orange (ratio 5:1) histograms. The results are representative of three independent experiments
with similar results.
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on the surface of T cells (Figure 9). All markers analyzed
were clearly not affected by the hMSCs present in the
upper compartment of the transwell system. This is in
disagreement with published reports indicating that soluble
factors are responsible for the immuno-suppressive effect
of hMSCs [30], as we show no difference between the acti-
vated T cells and the T cells that were cultured in a trans-
well system together with hMSCs. This may be due to the
fact that the experiments we performed were showing a
cross-species effect of hMSCs, while other reports based
their findings on a syngeneic or allogeneic reaction.
Discussion
Due to their immunosuppressive activities, hMSCs have
been used in many investigational clinical trials to inves-
tigate their potential to treat immunological disorders
or inflammation-mediated pathological lesions, including
Crohn’s disease, T1D and GVHD (reviewed in [16]). They
have also been investigated in co-transfer experiments
intended to improve the engraftment of allogeneic pancre-
atic islet transplant [31] and hematopoietic stem cells[32,33]. Because of the heterogeneous nature of hMSCs,
the establishment of quantitative bioassays that could
detect differences between hMSCs from different donors
and passages would potentially be of great value for
manufacturing and MSC product assessment purposes.
Currently, there is an increasing need to develop more
sensitive, accurately quantitative cell-based or in vitro
bioassays suitable for detecting small range differences in
immune-inhibitory activity of hMSCs from different donors
or at different passages in tissue culture, or under different
tissue culture expansion conditions. For example, the
traditionally used mixed lymphocyte reaction (MLR) is
a semi-quantitative, or relatively qualitative, rather than
quantitative assay; the result may be affected by many fac-
tors such as the mismatch extent of donor and recipient
MHC, gender and age of donor, as well as the previous
and current infectious disease status. With such inherent
variability, it can be very challenging to capture minor dif-
ferences in immunosuppressive activity between different
lots of hMSC products using the traditional MLR method.
It has been established that the immune inhibitory activ-
ity of MSCs works across allogeneic barriers, and it has
Figure 9 Effects of hMSCs on murine T cells are cell-contact dependent. A total of 2 × 106 CD4+ (panel A) or CD8+ (panel B) T cells were
cultured on the bottom well of a transwell system together with the specific peptide and APCs. The human bone marrow-derived mesenchymal
stem cells (hMSCs) were cultured in the upper well of the transwell system and the medium was shared between the two compartments. A total
of 72 hours later the T cells were stained with antibodies against CD25, CD69 and CD62L and analyzed using a FACS Canto flow cytometer. Un-
stimulated T cells are represented by a red histogram, stimulated T cells by a blue histogram and T cells that were co-cultured with hMSCs are
represented as green (ratio 10:1) and orange (ratio 5:1) histograms. The results are representative of three independent experiments, all with
similar results.
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survive and function to various extents in xenogenic
models, such as in mice and rats [18,26,34-36]. Therefore,
it is likely the immune inhibitory activity of the MSCs will
work across species, at least partially. For this reason, we
explored development of quantitative immune inhibition
assays using clonal murine T cell populations (derived from
TCR transgenic mice), known peptide antigens, and
MSCs from different human donors. Compared with
other existing systems, the advantages of this system in-
clude genetic and age variation between human T cell
donors is eliminated; the murine donors are kept under
specified pathogen free (SPF) conditions; the mouse TCRs
are monoclonal with known antigen specificity; and these
clonal mouse T cells are reliably available in essentially
unlimited supply.Through the work presented in the present study, we
discovered that hMSCs can inhibit the activation and
effector functions of mouse Ag specific T cells in response
to stimulation with cognate peptide antigens as well as
anti-CD3/anti-CD28. Many aspects of T cell activation are
affected, such as cell surface markers CD25, CD44,
CD62L, CD69, proliferation and cytokine production. The
effects are intrinsic to hMSCs, since control cell lines
(fibrosarcoma, hepatocellular carcinoma, fibroblasts) do not
exert these activities. To our knowledge, this is the first
report to demonstrate the cross-species effect of hMSCs
on clonal murine T cells when they are stimulated with
cognate peptide antigens.
Such an in vitro bioassay may be useful to assess the
immunosuppressive activity in human MSCs from different
donors, or to assess the effect of different tissue culture
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on their immuosuppressive activity. It might be particu-
larly valuable to researchers who have access to make
use of the animal resources as a supplementary method
when inter-donor (patient) variance is a major inter-
ference issue. Taking into consideration the fact that
obtaining TCR transgenic animals and purifying mouse T
cells is a relative cumbersome and probably not the most
cost-effective method, this method will not be applicable
to a routine cell therapy laboratory. However, if acceptable
reproducibility of the assay can be achieved through
optimization, potentially it might assist in informative
comparison of MSC lots and different manipulation
conditions.Figure 10 hMSCs from three different donors effect T cell activation a
cells) were isolated and purified from lymph nodes and spleens of NOD 8.3
cultured for three days in the presence of specific peptides and antigen-pre
cells (hMSCs) from three different donors (donor A, B and C) were added to
The cells were harvested, activation markers (CD25, CD69) were evaluated b
fluorescence intensity (MFI) increase was calculated as follows: (MFI increase
MFI increase of activated T cells without MSCs × 100%. Percent of inhibition
the culture supernatant were analyzed using a multiplex ELISA assay and th
donors (panel B). The graph is representative of two independent experimeDespite the fact that these results parallel previous
findings with allogeneic MSCs, some of the results obtained
in this study are not completely consistent with earlier
reports. For example, it has been reported that MSCs
preferentially skew the immune response toward Th2
over Th1 by inhibiting the production of TNF-α and
IFN-γ by CD4+ T cells (helper T cells) and CD8+ cytotoxic
T cells, while they up-regulate the expression of IL-10 and
IL-4 by CD4+ and CD8+ T cells [24]. From these results it
would be expected that hMSCs inhibit the production of
IFN-γ and the expression of transcription factor T-bet.
However, we also observed inhibition of IL-10 and the
Th2 transcription factor GATA-3. This could be due to
differences between our model systems (that is, thend cytokine production. Murine CD8+ T cells (8.3 TCR transgenic T
TCR transgenic mice using Miltenyi mouse CD8+ T cell isolation kit and
senting cells (APCs). Human bone marrow-derived mesenchymal stem
the wells at the beginning of the culture at a ratio of 5:1 (T cells:hMSC).
y flow cytometry and the percent inhibition of activation-induced mean
of activated T cells without MSCs - MFI increase of T cells with MSCs)/
was shown for all three donors (panel A). Cytokine concentrations in
e percent inhibition in cytokine production was shown for all three
nts with similar results.
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study, versus allogeneic hMSCs with human T cells; clonal
T cells versus polyclonal T cells, and so on). Also, it is
known that when TCR signal transduction pathways are
triggered with rigorous stimuli (such as PMA and iono-
mycin, anti-CD3 Ab) in T lymphocytes, both Th1 and
Th2 cytokines are released [37,38], and GATA-3 expres-
sion can be turned on by TCR signals [39,40]. Thus, it is
most likely that the inhibition of Th2 cytokines as well as
GATA-3 expression that we observed is merely a reflec-
tion of hMSC-mediated inhibition of TCR signaling and T
cell activation.
Although the mechanisms of immune regulation have
been extensively studied they are still not fully elucidated.
It is well-known that allogeneic MSCs can inhibit the
activation of T cells following stimulation with mitogenic
or allogeneic stimulation (PHA, Con A, CD3, allogeneic
PBL and so on) [9,10,41]. Also, peptide antigen-stimulated
T cell activation can be inhibited [11]. Several studies have
suggested that these immunoregulatory effects require
an initial cell-cell contact phase, but that suppressive
signaling is mediated by soluble factors including trans-
forming growth factor beta 1 (TGF-β1) [10], indoleamine
2,3-dioxygenase (IDO) [42], prostaglandin E2 (PGE2) [43],
nitric oxide (NO) [44], heme oxygenase-1 (HO-1) [45],
and insulin-like growth factor-binding proteins [46]. In
our study, the immunosuppression by hMSCs upon
both CD4+ and CD8+ T cells seems to be predominantly
mediated by a cell-cell contact mechanism. Perhaps the
cross-species effects of hMSCs are biologically different
from those in syngeneic or allogeneic systems studied
by others, which need to be further clarified. We plan to
test the immunosuppressive activities of mouse MSCs
on murine CD4+ and CD8+ T cell clones, to investigate
whether the effects we saw in this study are simply due
to the difference of cytokines or soluble factors between
mouse and human species.
There is controversy as to whether MSCs inhibit T
cell proliferation by inducing apoptosis or not. In our
experiments, we noticed a slight increase in Annexin V
expression when CD4+ T cells were incubated with
hMSCs, in agreement with one report that hMSCs can
induce apoptosis via a mechanism involving IDO and
IFN-γ [47]. Other studies have reported that hMSCs
inhibit the proliferation of T cells by non-apoptotic
mechanisms, such as cell cycle arrest [13,48]. Based on
previous reports, it is surprising to see in our system
that hMSCs can decrease apoptosis in activated murine
CD8+ T cells. We hypothesize that hMSCs might provide
certain soluble growth factors or cell-cell contact signals
that favor the survival of CD8+ T cells or prevent them
from activation-induced cell death. Further studies are
needed to gain better understanding of the underlying
mechanism.In all the experiments presented in this study we used
hMSCs isolated from a single donor (PCBM 1632), ex-
panded to passage number 3. Experiments with human
MSCs from several more donors demonstrated similar
immunosuppressive activities against murine clonal T
cells (our unpublished data). An example is shown in
Figure 10. Further studies are currently underway to
determine the molecular mechanism of immunosuppres-
sion, as well as to investigate whether further passaging
the hMSCs has any effect on their immune suppressive
function.
Since experimental results obtained from in vitro systems
do not always reflect the in vivo environment, they need
to be confirmed by in vivo findings. Ongoing experiments
are being performed in our group to further evaluate the
immuno-suppressive function of hMSCs in an in vivo
murine model of autoimmune type 1 diabetes. Previously,
MSCs obtained from healthy mice have been shown to
delay the onset of diabetes in non-obese diabetic (NOD)
mice [49]. Similarly, human MSCs lowered blood glucose
levels in the STZ- (streptozotocin-) treated diabetic mice
relative to untreated controls [18]. Once our in vivo studies
are finished, we may be able to correlate the in vivo inhibi-
tory functions of hMSCs with their in vitro activities, and
even identify potential biomarkers which can be used to
predict the in vivo efficacy before hMSC engraftment.
Conclusions
In summary, we established a system where the immuno-
suppressive activity of hMSCs can be measured using mur-
ine clonal T cells; several biomarkers were identified which
can be used to quantify the immunosuppressive activities of
hMSCs, such as CD25, CD44, CD62L, CD69, proliferation,
gene expression and cytokine production. Among these
markers, cytokine measurement is most quantitative and
easier to standardize, thus it could potentially contribute
to an informative comparison of MSC lots and their
potential manipulation.
Additional files
Additional file 1: Figure S1. hMSCs do not affect surface markers on
already activated T cells. Mouse CD8+ Ag specific T cells (8.3 T cells) were
stimulated with anti-CD3/CD28 Dynabeads (Invitrogen) (1:1 ratio of T cells:
beads) and human IL-2 (2,000 U/ml) for three days. Three days later, beads
were removed, T cells were then re-stimulated with IGRP peptide-pulsed
irradiated spleen cells, and human MSC were added to the culture at two
different ratios: 10:1 and 5:1 and further incubated for an additional three
days. Activation markers CD25 and CD69 for mouse 8.3 T cells were evaluated
and the mean fluorescence intensity was plotted for each condition. The
values are representative of three different experiments.
Additional file 2: Figure S2. The presence of hMSCs does not lead to
significant changes of Th17/Treg subsets. Purified mouse CD4+ Ag
specific T cells (BDC2.5 T cells) were cultured in the presence of Antigen
Presenting Cells and their cognate peptide for three days. hMSC were
co-cultured with the mouse T cells at a ratio of 5:1 T cells: MSC. For
measuring Th17 cells, T cells were stimulated with PMA (50 ng/ml) and
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http://stemcellres.com/content/4/5/128Ionomycin (1 μg/ml) in the presence of Golgi-Plug at 37°C for five hours.
Then surface staining with anti-CD4 and anti-TCR Vβ4 Abs,
permeabilization/fixation (using BD Cytofix/Cytoperm kit) and Intracellular
staining for mouse Foxp3 (eFluor450) and IL-17A (PE) was performed
according to the manufacture’s instruction (BD). The histograms are
representative of two separate experiments.
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